Home Life Sciences Hyperuricemia Therapeutics Assessment 2017

Hyperuricemia Therapeutics Assessment 2017


Hyperuricemia pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Sample copy is available at https://www.marketinsightsreports.com/reports/0504515/hyperuricemia-pipeline-and-therapeutics-development-h1-2017/inquiry

Companies Involved in Hyperuricemia Therapeutics Development are Allena Pharmaceuticals Inc, straZeneca Plc, CymaBay Therapeutics Inc, Jiangsu Hengrui Medicine Co Ltd, Nippon Chemiphar Co Ltd, Nobelpharma Co Ltd, olaris Pharmaceuticals Inc, Teijin Pharma Ltd.

Drug Profiles discussed in this research are ALLN-346 ,arhalofenate ,febuxostat ,FYU-981 ,HSA-Uricase ,JPH-367 ,NC-2500 ,NC-2700 ,NPCX-3 , pegadricase ,SHR-4640 ,Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia , Small Molecule to Inhibit Xanthine Oxidase for Hyperuricemia , Small Molecules to Inhibit Xanthine Oxidase for Hyperuricemia ,TMX-049 , verinurad.

The Hyperuricemia pipeline guide also reviews of key players involved in therapeutic development for Hyperuricemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 3, 4 and 5 respectively.

Get this report at https://www.marketinsightsreports.com/report/purchase/0504515?mode=su

Scope of this report:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperuricemia (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hyperuricemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hyperuricemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hyperuricemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hyperuricemia (Metabolic Disorders)


Please enter your comment!
Please enter your name here